Lung Cancer

Clinical Trials

Below is a list of Lung Cancer clinical trials from the clinical trials database at Mayo Clinic.

This list includes only trials about which Mayo researchers choose to publish information. Mayo Clinic may be conducting other trials which are not in this database. Mayo's clinical trials include experimental treatments, often unavailable elsewhere, which frequently lead to improved patient care for people worldwide. Patients should ask their doctor at Mayo about clinical trials appropriate for their situation.

A Phase II Study of Pemetrexed (Alimta) With Sorafenib (Nexavar) Versus Pemetrexed Alone as Second-line Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Patients are being asked to take part in this research study because they have been diagnosed with non-small cell lung cancer (NSCLC).

The purpose of this research study is to:
- Compare the effects, good and/or bad, of using BAY 43-9006 in combination with pemetrexed versus pemetrexed alone, on the patient's non-small cell lung cancer (NSCLC)
- Find out if there are individual differences and/or tumor characteristics that will affect response to treatment

BAY 43-9006 is an U.S. Food and Drug Administration (FDA)-approved drug for the treatment of kidney cancer. Pemetrexed is a standard chemotherapy drug that is used in patients with this type of lung cancer that did not respond to or that progressed after a first course of treatment.
Read more

Phase I/II Study of PS-341 (Velcade) in Combination with Paclitaxel (Taxol), Carboplatin, and Concurrent Thoracic (Lung) Radiation Therapy for Non-small Cell Lung Cancer (NSCLC)
This study is being done to find the highest dose of the investigational drug PS-341 that can be given in combination with carboplatin, paclitaxel, and radiation therapy without causing bad side effects.
Read more

A Phase 1b Dose Escalation/Phase 2 Randomized, Noncomparative, Multiple Center, Open Label Study of CP-751,871 in Combination with Paclitaxel and Carboplatin and of Paclitaxel and Carboplatin Alone as First Line Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC)
This study is being done to learn:
- The highest safe dose of the cancer drug called CP-751,871 that can be given every three weeks with paclitaxel and carboplatin to patients with cancer without causing bad side effects;
- About the side effects (good or bad) of CP-751,871, paclitaxel and carboplatin when given together;
- How the body handles or processes CP-751,871 when given with paclitaxel and carboplatin;
- If the patient's body generates antibodies (substances produced by the immune system to help fight infectious or foreign materials) against CP-751,871; and
- If CP-751,871 helps paclitaxel and carboplatin to fight the patient's cancer.

CP-751,871 is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA) for standard clinical use. This drug will be available to patients only during this study. Paclitaxel has been approved by the FDA for the treatment of lung cancer, but has not been approved in the combination used in this study, and its use is considered investigational. Carboplatin has been approved by the FDA for the treatment of ovarian cancer, but has not been approved in the combination used in this study, and its use is also considered investigational.
Read more

A Phase I Dose Escalation Study of the PKC Inhibitor, Aurothiomalate (ATM) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Background:
- PKCé is a protein that may help one type of lung cancer to grow.
- Gold sodium thiomalate (ATM) may block the effects of PKCé.
- This study is the first step in trying to find out if ATM can be used safely in the
treatment of the type of lung cancer that depends on PKCé for growth.
This study is being done:
- To find the highest dose of the PKCé inhibitor, ATM, that can be given to patients
with advanced non-small cell lung cancer (NSCLC) without causing bad side
effects;
- to learn if ATM can stop or slow the growth of a patient's NSCLC tumor;
- to learn about the side effects of ATM when given to patients with NSCLC; and
- to learn how the body handles or processes ATM and how ATM affects the body
using blood and tissue samples and in some cases, positron emission tomography
(PET) imaging.
Read more

A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab (Avastin) for Patients With Completely Resected (removed) Stage IB -IIIA Non-Small Cell Lung Cancer (NSCLC)
Patients are being asked to take part in this research study because they have non-small cell lung cancer, which has been removed by a surgeon. This research is being done because even with the most aggressive after-surgery treatment with chemotherapy, many people still have the lung cancer recur (come back).
The purpose of this study is to determine if adding the new drug bevacizumab to chemotherapy improves the chance for cure for patients who have had surgery for the removal of the lung cancer. The research staff will compare the effects (good and bad) of adding bevacizumab to chemotherapy with standard chemotherapy alone on the patient and their lung cancer to see which is better at preventing the cancer from coming back.
Read more

Contemporary Screening for the Detection of Lung Cancer (ACRIN #6654)

Purpose of the Study

To compare two ways of detecting lung cancer: digital chest X-ray and spiral computed tomography (CT) scan. This study aims to show which of these tests is best at detecting lung cancer at an early stage.

Abstract

Lung cancer is now the most common cause of cancer death among women and men. Despite considerable clinical research in multi-modality cancer treatment, there has been no significant decrease in lung cancer-specific mortality over the past three decades. Approximately 80% of lung cancers are of non-small cell histology, for which prognosis depends primarily upon tumor stage at the time of diagnosis. Although overall survival rates with non-small cell carcinoma are dismal, patients with surgical stage I disease may have 10-year survivals of up to 70%. This has formed the rationale for early detection programs. Previous large screening trials using combinations of chest radiographs and sputum cytology showed no significant improvement in lung cancer-specific or all-cause mortality among screened high-risk cohorts. However, contemporary computed tomography (CT) offers the potential to detect lung cancers at early stages amenable to surgical cure. This project involves using a multicenter, randomized controlled trial of 10,000 individuals at high risk of developing lung cancer to see whether screening with low-dose helical CT can reduce lung cancer-specific mortality relative to chest radiographs. A secondary objective is to create a bank of specimens from well-characterized high-risk cohorts that can be used to test future potential biomolecular markers of lung cancer. High risk will be defined by age 55-74 years with a current or previous heavy smoking history equaling at least 30 pack years; former smokers must have quit within the preceding 15 years. Prior to randomization, standardized eligibility, health, sociodemographic, and quality of life questionnaires as well as spirometry will be performed. Both Experimental and Control participants will provide blood, sputum and urine samples for archive at study entry and at the time of the first and second incidence screen. The Experimental group will undergo screening with low dose helical CT. The Control group will undergo screening with chest radiographs. Both groups will be screened annually for at least two incidence screens. Both groups will be contacted at six-month intervals to document interval health status and annually to complete quality of life questionnaires. Subgroups of both cohorts will complete questionnaires to determine the differential psychological impact of screening for lung cancer. Similarly, subgroups of Experimental and Control participants who have positive screening results will complete questionnaires to determine the psychological impact of positive screening tests, using as case-matched controls subgroups of Control and Experimental participants with negative screening CT results. The primary end-point of the trial is lung cancer-specific mortality. Intermediate end-points will include all-cause mortality; surgical stage at diagnosis; medical resource utilization; the impact of screening on quality of life and psychological effects; and the economic consequences of helical CT screening.
Read more

Detection of early cancer spread to lymph nodes in the chest in patients with lung cancer
The study evaluates minimally invasive and highly sensitive molecular methods to detect early cancer spread to lymph nodes. Lymph nodes are sampled with endoscopy and ultrasound-guided biopsy, then evaluated for genes associated with cancer spread.
Read more

Genetic Epidemiology Of Lung Cancer
The purpose of the study is to compare any inherited or genetic characteristics using blood or tissue specimens collected from individuals who have been diagnosed with lung cancer with the blood or tissue of their family members. The research study is funded by the National Cancer Institute and is part of a national research study being conducted by the Genetic Epidemiology of Lung Cancer Consortium (GELCC).
Read more

Minimally invasive staging of lung cancer
This study evaluates a novel, minimally invasive technique for determining whether lung cancer has spread to lymph nodes. The technique, endobronchial ultrasound, uses a very small, 5-6mm, ultrasound transducer inside the airways to view and guide a biopsy of lymph nodes in the central chest (mediastinum). The procedure is compared to existing techniques such as standard bronchoscopy, endoscopy and surgery.
Read more

Phase I Dose-Escalating, Open-Label, Non-Placebo Controlled Study of BAY 43-9006 (sorafenib, Nexavar) in Combination with Carboplatin, Paclitaxel (Taxol) and Bevacizumab (Avastin) in Previously Untreated Patients with Stage IIIB (with malignant pleural effusions) or Stage IV Non-Small Cell Lung Cancer (NSCLC)
This study is being done to learn:
-About the side effects (good or bad) of BAY 43-9006 (Sorafenib), carboplatin, paclitaxel and bevacizumab when given together;
-The highest safe dose of the cancer drug called BAY 43-9006 that can be given with carboplatin, paclitaxel and bevacizumab to patients with advanced nonsmall cell lung cancer;
-If BAY 43-9006, carboplatin, paclitaxel and bevacizumab fight the patient's cancer when given together;
-How much BAY 43-9006, carboplatin, paclitaxel and bevacizumab are in the patient's blood at specific times after they take the drugs.
Sorafenib, paclitaxel, carboplatin and bevacizumab have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of cancer, but have not been approved in the combination used in this study. Therefore, the use of this combination is investigational.
Read more

Randomized, Phase IIb Trial of Sulindac in Smokers with Bronchial Dysplasia
The purpose of this study is to find out what effects (good and bad) sulindac (CLINORIL®) has on patients and their risk of developing lung cancer.
Read more

SAMe for Smoking Cessation
The purpose of this study is to compare two doses of S-Adenosyl-L-Methionine (SAMe) or placebo (an inactive substance) to see if they can help smokers stop smoking.
Read more

Selenium Supplementation in Persons With Resected Stage I Non-Small Cell Lung Cancer (E5597)
This research study is being done to determine the effectiveness of selenium in preventing the development of second primary lung tumors in patients who have undergone surgery to remove non-small cell lung cancer.
Read more

Varenicline for the Treatment of Smokeless Tobacco Use
You are being asked to take part in this research study because you currently chew tobacco and wish to stop.
Read more